PDS Planning Inc Boosts Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

PDS Planning Inc raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.8% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 4,670 shares of the biopharmaceutical company’s stock after purchasing an additional 170 shares during the period. PDS Planning Inc’s holdings in Gilead Sciences were worth $431,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. HHM Wealth Advisors LLC increased its position in Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 154 shares during the period. YANKCOM Partnership purchased a new position in Gilead Sciences during the 4th quarter valued at about $28,000. Decker Retirement Planning Inc. purchased a new position in Gilead Sciences during the 4th quarter valued at about $29,000. Crews Bank & Trust purchased a new position in Gilead Sciences during the 4th quarter valued at about $31,000. Finally, Stephens Consulting LLC increased its position in Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 260 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Down 1.8 %

GILD stock opened at $110.23 on Wednesday. The firm’s fifty day simple moving average is $102.63 and its 200-day simple moving average is $93.38. The company has a market capitalization of $137.27 billion, a P/E ratio of 297.92, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be issued a dividend of $0.79 per share. The ex-dividend date is Friday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a yield of 2.87%. Gilead Sciences’s dividend payout ratio is 854.05%.

Analyst Upgrades and Downgrades

Several research analysts recently commented on GILD shares. DZ Bank upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price objective for the company in a research note on Thursday, February 13th. Mizuho boosted their price objective on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. Oppenheimer boosted their price objective on shares of Gilead Sciences from $115.00 to $132.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 4th. BMO Capital Markets boosted their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 12th. Finally, Royal Bank of Canada boosted their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a research note on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and an average price target of $104.52.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 142,180 shares of the stock in a transaction on Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $12,626,253.06. This represents a 52.26 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 302,785 shares of company stock valued at $30,503,250. Corporate insiders own 0.29% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.